[(2R)-3-[(2R)-2-amino-3-[[(1S)-1-(hydroxymethyl)-2-methoxy-2-oxo-ethyl]amino]-3-oxo-propyl]sulfanyl-2-hexadecanoyloxy-propyl]hexadecanoate hydrochloride

ID: ALA5195703

Chembl Id: CHEMBL5195703

PubChem CID: 168288905

Max Phase: Preclinical

Molecular Formula: C42H81ClN2O8S

Molecular Weight: 773.18

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCCCCCCCCCCCCC(=O)OC[C@H](CSC[C@H](N)C(=O)N[C@@H](CO)C(=O)OC)OC(=O)CCCCCCCCCCCCCCC.Cl

Standard InChI:  InChI=1S/C42H80N2O8S.ClH/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-39(46)51-33-36(34-53-35-37(43)41(48)44-38(32-45)42(49)50-3)52-40(47)31-29-27-25-23-21-19-17-15-13-11-9-7-5-2;/h36-38,45H,4-35,43H2,1-3H3,(H,44,48);1H/t36-,37+,38+;/m1./s1

Standard InChI Key:  MGBVNDUTHSYBNT-LXSLMTMVSA-N

Associated Targets(Human)

TLR2 Tchem TLR2/TLR6 (50 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Tlr2 TLR2/TLR6 (253 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 773.18Molecular Weight (Monoisotopic): 772.5635AlogP: 9.11#Rotatable Bonds: 39
Polar Surface Area: 154.25Molecular Species: NEUTRALHBA: 10HBD: 3
#RO5 Violations: 2HBA (Lipinski): 10HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.53CX Basic pKa: 8.06CX LogP: 10.68CX LogD: 9.94
Aromatic Rings: Heavy Atoms: 53QED Weighted: 0.03Np Likeness Score: 0.38

References

1. Kaur A, Piplani S, Kaushik D, Fung J, Sakala IG, Honda-Okubo Y, Mehta SK, Petrovsky N, Salunke DB..  (2022)  Stereoisomeric Pam2CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants.,  13  (5.0): [PMID:35694694] [10.1039/d1md00372k]

Source